NCT06904625Recruiting
Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
This trial is a pilot, prospective, single-center study conducted in a population of patients with metastatic breast cancer (whatever the immunohistochemical subtype) or metastatic prostate cancer. The aim of this exploratory study is to compare the sensitivity of three different techniques (CellSearch®, Parsortix® and SmartCatch®) in detecting circulating tumor cells (CTCs). After the patient's agreement, and before starting anti-tumor treatment, a blood sample will be taken using the 3 different CTC detection techniques. Each patient will participate in the study for one day. A total of 54 evaluable patients (36 patients with metastatic breast cancer and 18 patients with metastatic prostate cancer) will be included in this interventional study.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 25 Mar 2025
- Start date
- 14 Aug 2025
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Institut Claudius Regaud
- Diseases
- Prostate cancer, Metastatic breast cancer
- NCT number
- NCT06904625
What you commit to
- Study type: Interventional
- Planned participants: 54
- From 14 Aug 2025 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures stipulated in the study protocol.
Other
- Associated pathology(ies) likely to prevent the study procedure from running smoothly
- Patient deprived of liberty or under legal protection (guardianship, legal protection)
- Patient who has had another solid tumor (excluding carcinoma in situ of the breast or cervix) within 5 years.
Who the study is looking for
- Patient with breast cancer (whatever the immunohistochemical subtype: triple-negative, RH+/HER2-negative or HER2-positive) or prostate cancer, multi-metastatic, eligible for a new line of treatment.
- Patient not yet initiated on a new specific treatment for breast or prostate cancer at inclusion.
- Age ≥ 18 years and WHO ≤ 2
- Patient affiliated to Social Security scheme in France.
- Patient having signed informed consent prior to inclusion in the study and prior to any study-specific procedures.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IUCT-O Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.